Lantern Pharma Q2 EPS $(0.57) Misses $(0.38) Estimate

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.38) by 50 percent. This is a 42.5 percent decrease over losses of $(0.40) per share from the same period last year.